Cheyenne, Wyoming — October 31, 2025 — Leads & Copy — CS Diagnostics Corp. (OTCQB:CSDX) announced that its affiliates, CS Interpharm and CS Diagnostics Pharma, have completed the conversion of their holdings in the company’s Series B Preferred Stock into unrestricted common stock.
This conversion marks a step in CSDX’s plan to consolidate financial statements across all affiliated entities by the end of the fiscal year. The conversion is expected to provide benefits such as increased transparency, improved efficiency, and value creation for shareholders.
Resales of converted shares by affiliates remain subject to Rule 144 of the Securities Act of 1933, including Form 144 Filings, volume restrictions and public information requirements.
“This share conversion is not merely a technical adjustment but a forward-thinking strategic initiative that underscores our commitment to unity, innovation, and sustainable growth,” said Mohammad EsSayed, Principal Financial Officer of CS Diagnostics Corp.
Mohammad Essayed, Email: info@csdcorp.us
Source: CS Diagnostics Corp.
